While the early arrival of spring weather has many of us turning our attention to our gardends, pharmaceutical companies are facing a number of new developments in the patent landscape. In this podcast interview for  The Burrill Report, I talk about Prometheus, Myriad, the compulsory license for Bayer’s Nexvar drug in India, and the status of the implementation of U.S. patent reform.

If you’ve been spending more time enjoying nature than drawing lines between laws of nature and products of nature, I’ll get you caught up in a few minutes.